clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03838263 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | France | Q142 |
P582 | end time | 2020-12-01 | |
P921 | main subject | nivolumab | Q7041828 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 61 | |
P4844 | research intervention | cisplatin | Q412415 |
P6153 | research site | Institut Gustave Roussy | Q266227 |
Curie Institute | Q2451973 | ||
Beaujon Hospital | Q2690409 | ||
hôpital Foch | Q3145155 | ||
Tenon Hospital | Q3145241 | ||
??? | Q2944818 | ||
P1813 | short name | IMMUNEBOOST | |
P580 | start time | 2019-03-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer |
Search more.